Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for lung cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell LungCancer: A Review. Non-small cell lungcancer remains the leading cause of cancer death in the United States. Until the last decade, the 5-year overall survival rate for patients with metastatic non-small cell lungcancer was less than 5%. Improved understanding of the biology of lungcancer has resulted in the development of new biomarker-targeted therapies and led to improvements in overall survival for patients (...) with advanced or metastatic disease.Systemic therapy for metastatic non-small cell lungcancer is selected according to the presence of specific biomarkers. Therefore, all patients with metastatic non-small cell lungcancer should undergo molecular testing for relevant mutations and expression of the protein PD-L1 (programmed death ligand 1). Molecular alterations that predict response to treatment (eg, EGFR mutations, ALK rearrangements, ROS1 rearrangements, and BRAF V600E mutations) are present
Lorbrena - anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lungcancer Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs
Durvalumab (Imfinzi) for the treatment of locally advanced, unresectable, non-small cell lungcancer Durvalumab (Imfinzi®) for the treatment of locally advanced, unresectable, non-small cell lungcancer | Report | National Health Care Institute You are here: Durvalumab (Imfinzi®) for the treatment of locally advanced, unresectable, non-small cell lungcancer Search within English part of National Health Care Institute Search Durvalumab (Imfinzi®) for the treatment of locally advanced (...) , unresectable, non-small cell lungcancer Zorginstituut Nederland has completed its assessment of durvalumab (Imfinzi®) as monotherapy for the treatment of locally advanced, unresectable, non-small cell lungcancer (NSCLC). Due to its expected high costs the Minister of Health, Welfare and Sport (VWS) has placed durvalumab in the so-called ‘waiting room’ or ‘sluice’ for expensive drugs. These products can only be accepted into the insured package after the Zorginstituut has advised on their inclusion
The Optimal Treatment for Stage IIIA-N2 Non-Small Cell LungCancer: A Network Meta-Analysis The optimal treatment for stage IIIA-N2 non-small cell lungcancer (NSCLC) is controversial. We aimed to address this important issue through a Bayesian network meta-analysis.We performed a search of electronic databases for randomized controlled trials comparing the following treatments: surgery, radiotherapy, chemotherapy, and their multiple combinations before March 25, 2018. Pooled data on overall
Exercise training undertaken by people within 12 months of lung resection for non-small cell lungcancer. Decreased exercise capacity and health-related quality of life (HRQoL) are common in people following lung resection for non-small cell lungcancer (NSCLC). Exercise training has been demonstrated to confer gains in exercise capacity and HRQoL for people with a range of chronic conditions, including chronic obstructive pulmonary disease and heart failure, as well as in people with prostate (...) and breast cancer. A programme of exercise training may also confer gains in these outcomes for people following lung resection for NSCLC. This systematic review updates our 2013 systematic review.The primary aim of this review was to determine the effects of exercise training on exercise capacity and adverse events in people following lung resection (with or without chemotherapy) for NSCLC. The secondary aims were to determine the effects of exercise training on other outcomes such as HRQoL, force
Interventions for smoking cessation in people diagnosed with lungcancer. Lungcancer is one of the most common causes of death from cancer worldwide. Smoking induces and aggravates many health problems, including vascular diseases, respiratory illnesses and cancers. Tobacco smoking constitutes the most important risk factor for lungcancer. Most people with lungcancer are still active smokers at diagnosis or frequently relapse after smoking cessation. Quitting smoking is the most effective (...) way for smokers to reduce the risk of premature death and disability. People with lungcancer may benefit from stopping smoking. Whether smoking cessation interventions are effective for people with lungcancer and whether one method of quitting is more effective than any other has not been systematically reviewed.To determine the effectiveness of smoking cessation programmes for people with lung cancer.We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (accessed via
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lungcancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial Resistance to first-generation or second-generation EGFR tyrosine kinase inhibitor (TKI) monotherapy develops in almost half of patients with EGFR-positive non-small-cell lungcancer (NSCLC) after 1 year of treatment. The JO25567 phase 2 trial comparing erlotinib plus bevacizumab
Effect of Vein-First vs Artery-First Surgical Technique on Circulating Tumor Cells and Survival in Patients With Non-Small Cell LungCancer: A Randomized Clinical Trial and Registry-Based Propensity Score Matching Analysis It is important to develop a surgical technique to reduce dissemination of tumor cells into the blood during surgery.To compare the outcomes of different sequences of vessel ligation during surgery on the dissemination of tumor cells and survival in patients with non-small (...) cell lung cancer.This multicenter, randomized clinical trial was conducted from December 2016 to March 2018 with patients with non-small cell lungcancer who received thoracoscopic lobectomy in West China Hospital, Daping Hospital, and Sichuan Cancer Hospital. To further compare survival outcomes of the 2 procedures, we reviewed the Western China LungCancer database (2005-2017) using the same inclusion criteria.Vein-first procedure vs artery-first procedure.Changes in folate receptor-positive
Brigatinib (Alunbrig) - for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lungcancer (NSCLC) Published 10 June 2019 1 SMC2147 brigatinib 30mg, 90mg and 180mg film-coated tablets (Alunbrig®) Takeda UK Ltd 10 May 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows (...) : ADVICE: following a full submission assessed under the end-of-life and ultra-orphan medicine process brigatinib (Alunbrig®) is accepted for use within NHSScotland. Indication under review: as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lungcancer (NSCLC) previously treated with crizotinib. Brigatinib was associated with an objective response rate of 56% in a single-arm, open- label, phase II study in patients with ALK
Durvalumab (Imfinzi) - for the treatment of locally advanced, unresectable non-small cell lungcancer (NSCLC) Published 10 June 2019 1 SMC2156 durvalumab 50mg/mL concentrate for solution for infusion (Imfinzi®) AstraZeneca 10 May 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission (...) considered under the ultra-orphan and end of life process durvalumab (Imfinzi®) is accepted for use within NHSScotland. Indication under review: as monotherapy for the treatment of locally advanced, unresectable non-small cell lungcancer (NSCLC) in adults whose tumours express PD-L1 [programmed cell death ligand 1] on =1% of tumour cells and whose disease has not progressed following platinum-based chemoradiation therapy. Durvalumab, compared with placebo, improved progression-free survival and overall
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lungcancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. First-line pembrolizumab monotherapy improves overall and progression-free survival in patients with untreated metastatic non-small-cell lungcancer with a programmed death ligand 1 (PD-L1) tumour proportion score (TPS) of 50% or greater. We investigated overall survival after treatment (...) with pembrolizumab monotherapy in patients with a PD-L1 TPS of 1% or greater.This randomised, open-label, phase 3 study was done in 213 medical centres in 32 countries. Eligible patients were adults (≥18 years) with previously untreated locally advanced or metastatic non-small-cell lungcancer without a sensitising EGFR mutation or ALK translocation and with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1, life expectancy 3 months or longer, and a PD-L1 TPS of 1% or greater
2019LancetControlled trial quality: predicted high
Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell LungCancer Using a Clinicogenomic Database. Data sets linking comprehensive genomic profiling (CGP) to clinical outcomes may accelerate precision medicine.To assess whether a database that combines EHR-derived clinical data with CGP can identify and extend associations in non-small cell lungcancer (NSCLC).Clinical data from EHRs were linked with CGP results for 28 998 patients (...) EHRs.Overall survival (OS), time receiving therapy, maximal therapy response (as documented by the treating physician in the EHR), and clinical benefit rate (fraction of patients with stable disease, partial response, or complete response) to therapy.Among 4064 patients with NSCLC (median age, 66.0 years; 51.9% female), 3183 (78.3%) had a history of smoking, 3153 (77.6%) had nonsquamous cancer, and 871 (21.4%) had an alteration in EGFR, ALK, or ROS1 (701 [17.2%] with EGFR, 128 [3.1%] with ALK, and 42 [1.0
Alectinib (non-small cell lungcancer) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Alectinib (nicht kleinzelliges Lungenkarzinom) – Nutzenbewertung gemäß § 35a SGB V (neues Anwendungsgebiet) (Version 1.0; Status: 28 March 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding (...) . IQWiG Reports – Commission No. A17-67 Alectinib (non-small cell lungcancer) – Benefit assessment according to §35a Social Code Book V 1 (new therapeutic indication) Extract of dossier assessment A17-67 Version 1.0 Alectinib (non-small cell lungcancer) 28 March 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Alectinib (non-small cell lungcancer) – Benefit assessment according to §35a